Last updated on April 16, 2014 at 1:21 EDT

uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy

June 18, 2012

AMSTERDAM, The Netherlands, June 18, 2012 /PRNewswire/ –

uniQure, a leader in the field of human gene therapy, announced today the extension of
its collaboration with Protein Sciences Corporation (“Protein Sciences”) for the exclusive
use of Protein Sciences’ expresSF+(R) (SF+) insect cell line in uniQure’s AAV gene therapy
programs for three specific disease indications. uniQure has the option to extend this
exclusivity further into additional indications in the future.

“This agreement strengthens uniQure’s gene therapy platform and further demonstrates
the quality of the cell line developed by Protein Sciences.” said Joern Aldag, Chief
Executive of uniQure. “Protein Sciences’ cell line license agreement with Merck made
earlier this year and the anticipated approval of its influenza vaccine FluBlok(R) implies
SF+ technology will hold a prominent place in the manufacture of biologics.”

The SF+ cell line developed by Protein Sciences is an integral component of uniQure’s
validated, world leading manufacturing platform. uniQure believes that this platform is
the only commercially-scalable platform available for manufacturing AAV gene therapy

Financial terms were not disclosed.

About uniQure

uniQure is a world leader in the development of human gene based therapies. uniQure
has a product pipeline of gene therapy products in development for hemophilia B, acute
intermittent porphyria, Parkinson’s disease and SanfilippoB. Using adeno-associated viral
(AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate probably the world’s first stable and scalable AAV
manufacturing platform. This proprietary platform can be applied to a large number of rare
(orphan) diseases caused by one faulty gene and allows uniQure to pursue its strategy of
focusing on this sector of the industry. Further information can be found at



Source: PR Newswire